Bristol-Myers Squibb ( BMY) is buying biotech firm Medarex ( MEDX) for $2.1 billion to bolster the U.S. drugmaker's drug pipeline and capability to produce biologic drugs. The deal, announced Wednesday night, values Medarex at $16 a share, a 90% premium to the company's $8.40 a share closing price. A $2.4 billion purchase price, which Bristol-Myers will pay in cash, is offset by $300 million on Medarex's books. Medarex specializes in the production of protein-based drugs made in living cells engineered to produce human antibodies. These so-called biologic drugs are different from the chemical-based drugs typically developed and marketed by large pharmaceutical companies. Bristol-Myers and Medarex already were partners on one such drug, ipilimumab, currently in a phase III study of skin cancer patients. "Medarex's technology platform, people and pipeline provide a strong complement to our company's biologics strategy, specifically in immuno-oncology," said Bristol-Myers CEO James Cornelius, in a statement. Medarex hasn't successfully developed any drugs on its own yet, but three drugs it helped manufacture for partners have been approved recently -- Johnson & Johnson's ( JNJ) Simponi and Stelara and Novartis' ( NVS) Ilaris. Medarex receives royalties on the sale of these products. The company has seven drugs of its own in current clinical trials and another three under development by partners. Bristol-Myers' decision to acquire Medarex, a biotech drug development partner, comes a little less than a year after Bristol-Myers was outbid to acquire another partner, the biotech firm ImClone Systems. Eli Lilly ( LLY) purchased ImClone, developer of the cancer drug Erbitux, for $6.5 billion -- a bid that trumped Bristol-Myer's $4.7 billion bid.
Medarex is run by CEO Howard Pien, who in a previous stint as CEO of Chiron, sold that biotech firm to Novartis. Bristol-Myers' purchase of Medarex takes the form of an all-cash tender offer starting on July 27. As part of the agreement, Medarex has pledged not to solicit any competing offers for the company. Bristol-Myers is paying for the deal with its cash on hand.